Mylan Appoints Heather Bresch as Chief Operating Officer

Mylan Appoints Heather Bresch as Chief Operating Officer

October 03, 2007

Promoted from Head of North America


    PITTSBURGH, Oct. 3 /Xinhua-PRNewswire/ -- Mylan Inc.
(NYSE: MYL) today announced the appointment of Heather
Bresch as Chief Operating Officer.  Ms. Bresch served
previously as Head of North America and Chief Integration
Officer.  As Chief Operation Officer, Ms. Bresch will be
responsible for Mylan's global commercial and technical
operations, strategic planning, business development and
international affairs, which includes development of
Mylan's antiretroviral (ARV) franchise.  She will also
continue to oversee the integration of Mylan's recent
acquisition of Merck Generics.

    Ms. Bresch has spent fifteen years with Mylan in
various positions of increasing responsibility throughout
the company.  Most recently, as Head of North America, she
had responsibility for Mylan's operations including Mylan
Pharmaceuticals, Mylan Technologies, and UDL Laboratories. 
Prior to this, she served as Senior Vice President of
Strategic Development in the Office of the CEO.

    In her role as Chief Integration Officer, in addition
to leading the integration team working with Merck
Generics, Ms. Bresch has overseen the successful
integration of Matrix Laboratories, in which Mylan took a
controlling stake earlier this year. 

    Ms. Bresch has been the only non-CEO to serve as
Chairman of the Generic Pharmaceutical Association (GPhA),
serving an unprecedented two consecutive terms, and is
widely acknowledged in the industry for playing a critical
role in the passage of the 2003 Medicare Modernization Act,
a Congressional revision to the Hatch-Waxman Act of 1984
that focused on ensuring consumers' access to affordable
pharmaceuticals. 

    Mylan's Vice Chairman and CEO Robert J. Coury
commented:  "At this stage in Mylan's history, it is
imperative that we have a Chief Operating Officer in place
that knows our company, is a leader in the industry and has
the experience and energy required to execute on the
opportunities of the new Mylan.  Heather is uniquely
qualified for this challenging position, given her in-depth
knowledge of Mylan, Matrix and Merck Generics and her strong
relationships with management and employees across those
organizations as a result of leading the integration
efforts.  She has played an instrumental role in Mylan's
strategic development over the last several years, and will
continue to be a key driver of the Company's future
success."

    Ms. Bresch earned an MBA and an undergraduate degree in
international studies and political science from West
Virginia University. 

    Mylan Inc. is one of the world's leading quality
generic and specialty pharmaceutical companies. The Company
offers one of the industry's broadest and highest quality
product portfolios, a robust product pipeline and a global
commercial footprint through operations in more than 90
countries.  Through its controlling interest in Matrix
Laboratories Limited, Mylan has direct access to one of the
largest active pharmaceutical ingredient (API) manufacturers
in the world.   Dey L.P., Mylan's fully integrated specialty
business, provides the Company with innovative and
diversified opportunities in the respiratory and allergy
therapeutic areas.  

    For more information about Mylan, please visit
http://www.mylan.com .


    For more information, please contact:

     Kris King, 
     Mylan Inc.
     Tel:  [phone]